cebo groups were noted in that end point at months 1 and 4, but only trends were observed at month 12. These differences were observed even though the serum mexiletine levels obtained in this study were generally lower than those observed in studies that have used the regular form of the drug. There were more deaths in the mexi1etine group (7.6%) than in the placebo group (4.8%)j the difference was not statistically significant. The incidence of coronary events was similar in both groups. Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.
International Mexiletine and Placebo Antiarrhythmic Coronary Trial: I. Report on Arrhythmia and Other Findings
IMPACT RESEARCH GROUP* The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction. The primary response variable was based on central reading of 24 hour ambulatory electrocardiographic recordings and was defined as the occurrence of 30 or more single premature ventricular complexes in any two consecutive 30 minute blocks or one or more runs of two or more premature ventricular complexes in the entire 24 hour electrocardiographic recording. Large differences, regarded as statistically significant, between the mexiletine and piaPrevention of sudden cardiac death after myocardial infarction remains a major challenge. It is generally accepted that ventricular arrhythmias are a major cause of death in the patient with myocardial infarction, both before and after admission to the hospital (1). Because of the strong association between ventricular arrhythmias and the risk of sudden cardiac death for such patients, it seems logical to attempt to prevent sudden death by long-term antiarrhythmic treatment. This latter approach is reinforced by the fact that observed mortality from acute myocardial infarction has been declining (2, 3) , possibly , in part because of prompt treatment of serious arrhythmias detected by continuous monitoring of patients with myocardial infarction in coronary care units.
The International Mexiletine and Placebo Antiarrhythmic Coronary Trial (IMPACT) was initiated to ascertain whether the sustained release form of mexiletine (Mexitil-Perlongets) would be effective in reducing the occurrence of ventricular arrhythmia in patients with recent documented myocardial infarction. Short-term controlled studies (4, 5) had shown that mexiletine was effective in reducing the rate of premature ventricular beats in patients prone to arrhythmias. These same studies and long-term noncontrolled studies (6, 7) indicated that mexiletine did not induce dangerous side effects . The sustained release form of mexiletine was selected for study because it had been demon strated to yield constant blood levels with only two doses per day and also had fewer side effects than the regular form (8) . The study was also designed to study the safety and patient tolerance of the drug compared with placebo during the first 12 months after an acute event. The occurrence of both fatal and nonfatal events was monitored.
It was thought that before embarking on a large scale secondary prevention study of the sustained release form of mexiletine , a controlled trial to assess the antiarrhythmic effects as well as patient tolerance should be undertaken in a group of patients with moderate mortality risk after myocardial infarction . Results from a study (9) of the regular form of mexiletine conducted in the United Kingdom in patients judged to be at high risk after acute myocardial infarction suggested that high risk patients might not benefit from prophylactic antiarrh ythmic therapy .
Methods Study organization. Nine clinical centers in Europe and
North America (one in Belgium, one in Canada, two in France, one in The Netherlands, one in Scotland and three 0735 -1097/84/$3 .00 in the United States) participated in this trial. To accommodate the international nature of the study, there were two Regional Coordinating Centers-one in Baltimore, Maryland for the North American clinics and one in Lyon, France for the European clinics. All electrocardiograms were read at one Electrocardiogram Center in Rotterdam , The Netherland s. A Central Laboratory was located in Van Nuys, California. A Data Audit Center in Chicago, Illinois functioned as a secondary data analysis center and monitored the performance of the two Regional Coordinating Centers. The Drug Procurement and Distribution Centers, responsible for coding and packaging the study drugs under the guidance of the Regional Coordinating Centers, were located in Elmsford, New York and Ingelheim, West Germany.
A Planning Board was responsible for the initial development of the study protocol and functioned until an independent Policy Board was established to direct the study . The Policy Board had final responsibility for the scientific conduct of the study. It consisted of permanent members who were not associated with the operation of the trial or with the sponsor and ex officio members representing the study leadership. The other administrative units of the study included a Steering Committee, Executive Committee, Data Monitoring Committee and Mortality and Morbidity Classification Committee . The study was financed by a grant from Boehringer Ingelheim International, Ltd. , Ingelheim , West Germany.
Patient eligibility and exclusion criteria. Men aged 30 to 74 years and women aged 45 (to exclude women of childbearing potential) to 74 years who were admitted to a hospital coronary care unit in the participating Clinical Centers and \Ii ho had evidence of a recent myocardial infarction were screened for eligibility for this study and registered in the Clinical Center log books. The eligibility and exclusion criteria were defined with the intent of enrolling patients with moderate risk of mortality after myocardial infarction and without regard to the presence or absence of arrhythmia. The clinic physician considered a patient to have had a documented myocardial infarction if there was 1) a typical history and Q/QS changes (on comparison of two recent electrocardiograms), 2) serum enzyme elevations and Q/QS changes, or 3) a typical history , serum enzyme elevations and either (a) Q/QS findings plus ST or T wave abnormalities , or both, (b) ST segment deviations , or (c) T wave changes. The Minnesota Code for classification of electrocard iographic changes was used for this assessment. The patients who met the diagnostic criteria and who appeared eligible after a comprehensive medical examination were invited to participate in the study . If, after a full explanation of the purposes of the study and its possible risks and benefits. the patient gave written informed consent, a 12 lead rest electrocardiogram and a 24 hour ambulatory electrocardiogram were taken. A baseline examination that involved final assessment of eligibility was completed after the patient was in a stable condition. This examination was completed no sooner than 72 hours and no later than 25 days after admission to the hospital.
Conditions that excluded a patient permanently from the study were: congestive heart failure that could not be controlled by digitalis or diuretic drugs, or both; cardiogenic shock; Wolff-Parkinson-White syndrome; sick sinus syndrome ; Parkinsonism, epilepsy or organic neurologic disorder ; history of adverse reaction to mexiletine; history of hypersensitivity to local anesthetics of the amide type, such as lidocaine; myocardial infarction resulting from surgery, angiography, trauma, hypoglycemic shock, infectious endocarditis, aortic dissection, embolism with normal coronary arteries or carbon monoxide intoxication; need for therapy with other antiarrhythmic drugs or antianginal drugs other than long-acting nitrates ; or any condition that was associated with reduced likelihood of survival or made it unlikely the patient would adhere to the protocol. A patient was also ineligible if any of the following conditions were present at the time of the qualifying examination: complete left bundle branch block ; heart rate of less than 50 beats/min; second or third degree atrioventricular (AV) block; symptomatic hypotension or systolic blood pressure of less than 90 mm Hg. If all these conditions were absent for 72 hours within 25 days of entry into the hospital , the patient was then eligible to complete the baseline examination.
As soon as the baseline examination was completed, a request for allocation was sent by telecopier to the appropriate Regional Coordinating Center. The Regional Coordinating Center staff reviewed the request for allocation and if the patient was judged eligible, a treatment allocation was issued and transmitted immediately to the clinic.
Treatment regimens. Mexiletine capsules and corresponding placebo capsules were administered in a doubleblind manner. Each patient was instructed to take daily one capsule of assigned medication (either mexiletine, 360 mg, or placebo) during breakfast and one capsule during the evening meal. Dosage decreases in both the mexiletine and placebo groups were to be made by the study physician if serious side effects occurred. Neurologic or psychologic side effects, such as parkinsonism or psychotic reactions required permanent discontinuation. The protocol also recommended temporary discontinuation of assigned study medication if any of the following conditions occurred: second or third degree AV block , ventricular fibrillation or symptomatic ventricular tachycardia , congestive heart failure that could not be controlled by digitalis or diuretic drugs and prescription of any antiarrythmic drugs (except digitalis) or any antianginal drugs other than long-acting nitrates. Study medication did not have to be discontinued if betareceptor blocking agents were prescribed. The protocol noted that available information indicated that the only reported IMPACT RESEARCH GROUP ixcc Vol. 4, No.6 December 1984 :1148 adverse effect of the combined use of mexiletine and betareceptor blocking agents was the possible occurrence of bradycardia.
Examination schedule and procedures. Each patient was asked to return to the clinic for follow-up examinations at I, 2, 4, 8 and 12 months after entry into the study. Each visit included a medical history~physical examination, local laboratory tests of urine and blood specimens, assessment of adherence to study medication and collection of blood specimens for determination of serum mexiletine levels and other biochemical determinations at the Central Laboratory. The occurrence of nonfatal cardiovascular and noncardiovascular events was ascertained on the basis of data collected at these visits. A 12 lead rest electrocardiogram and 24 hour ambulatory electrocardiogram were obtained at the followup visits completed at 1, 4 and 12 months after entry. A 6 foot (or 2 meter) posteroanterior chest X-ray film was taken at the visit scheduled 12 months after entry. Urinalysis, hematocrit and white blood cell count were performed in the local laboratory of each of the clinical centers.
All electrocardiograms were obtained using Oxford Medilog recorders and were graded at the Electrocardiogram Reading Center without knowledge of treatment assignment or clinical findings. The 24 hour electrocardiograms were analyzed on the Argusl2H system (10), with counts of premature ventricular complexes, doublets or runs recorded for each of the forty-eight 30 minute blocks. Additional findings were reported for the entire 24 hour recording. For quality control, a trained observer reviewed one 30 minute block and counted the premature ventricular complexes, doublets or runs in that block. In addition, a time-stratified random sample of tapes was submitted for rereading in such a way that the technician readers did not know the tape had been read previously.
Primary end points. Review of the published data indicated' that no single set of arrhythmic markers can be accepted as predictive of sud~en cardiac death (II). It has been observed (12) that frequent premature ventricular complexes may precede ventricular fibrillation in patients who are being monitored in the coronary care unit, but others (13) have been unable to find warning arrhythmias in the early stages of myocardial infarction based on morphology or timing of premature ventricular complexes that would identify patients at high risk of ventricular fibrillation in the coronary care unit.
One approach to assessing efficacy of antiarrhythmic therapy has been to measure the reduction in rate of baseline premature ventricular complexes. This approach could not be used in IMPACT for two reasons. First, it was anticipated (and subsequently confirmed by IMPACT data) that the rate of premature ventricular complexes, at least in the placebo group, would increase once the patients were discharged from the hospital, engaged in greater physical activity and were more exposed to life stresses. Second, IMPACT was a study of prevention as well as treatment of cardiac arrhythmias and patients were eligible whether arrhythmia was absent or present.
Arrhythmia response end point. During the planning phase, the IMPACT investigators defined the primary response variable for this study as the occurrence of 30 or more single premature ventricular complexes in any two consecutive 30 minute blocks or one or more runs of two or more premature ventricular complexes in the entire 24 hour electrocardiographic recording assessed on the basis of the grading of the 24 hour electrocardiogram recordings at the Electrocardiogram Reading Center. This response variable is denoted here as frequent or complex cardiac arrhythmia. Thus, the primary arrhythmia end point included arrhythmia variables that could be measured by ambulatory monitoring and that were presumed to be predictive of the occurrence of ventricular fibrillation and, therefore, presumably predictive of sudden cardiac death. Review of previously reported studies indicates that this relation has not been established, although data from the Coronary Drug Project (14) indicated an excess risk of death, including sudden death, was associated with the frequency of premature beats in the rest 12 lead electrocardiogram. The IMPACT definition of frequent or complex cardiac arrhythmia includes Lown classes 2 (that is, peak rate~30 premature ventricular complexes/h), 4A (that is, doublets) and 4B (that is, runs of three or more premature ventricular complexes) (15) . Other arrhythmia response variables were also defined and evaluated in IMPACT.
Reports of hospitalization and mortality were reviewed by the Mortality and Morbidity Classification Committee without knowledge of treatment assignment. This committee classified each event according to previously defined criteria.
Data monitoring. Data reports were reviewed semiannually by the Data Monitoring Committee. The reports included data on arrhythmia end points, nonfatal and fatal events, possible side effects, biochemical findings, quality control and patient adherence to protocol prescription. The protocol specified that the decision to extend or expand the study would be based on the analysis of the readings of the 24 hour electrocardiographic recordings obtained at 4 months and the limited information available for later months in conjunction with the data on side effects and fatal and nonfatal events; this decision was to be made approximately I year after patient recruitment started.
Sample size and randomization. The minimal number of patients was 600; the goal for each clinic was 75 patients.
This sample provided a reasonable chance (power = 0.89) of detecting a difference if, after 4 months of treatment, the rate of frequent or complex cardiac arrhythmia in placebotreated patients was 30% and the rate in mexiletine-treated patients was 18% (40% reduction). With this sample size, there \\ as only a small chance (power = O. 17) of detecting a 20 to 25% reduction in the I year mortality if the mortality rate in the placebo group was approximately 10%.
Separate randomization schedules were prepared for each clinical center and were designed to balance, at specified intervals throughout the period of recruitment, the number of patients assigned to the mexiletine and placebo groups. There were no other stratification variables.
Study timetable. Patient recruitment started February 15, 19~I and terminated March 31, 1982; 630 patients were enrolled (317 assigned to mexiletine and 313 to placebo). Nineteen percent of the patients entering the participating clinica I centers' coronary care units with a diagnosis of myocardial infarction were actually enrolled in the study. After review of all available data in April 1982, the Data Monitoring Committee concluded that an expanded longterm secondary prevention study was not warranted and recommended that follow-up study of all patients be terminated. The Policy Board endorsed this recommendation, which was then implemented by the study investigators. In the penod between May I, 1982 and August 31, 1982, all survivmg patients were scheduled for a final visit at which study treatment was discontinued. Any event including death that occurred before the date of the final scheduled visit was counted for the assessment of treatment effects. Each surviving patient was seen in October or November 1982, at which time he or she was given a summary of the study results and informed of the treatment received during the study.
Statistical methods. Mexiletine-placebo differences in the proportion of fatal and nonfatal events were assessed by calculating Z values, that is, the difference between the proportions in the two groups divided by the standard error of the difference. The results of life table analyses, calculated using the product-limit method (16) , are also reported for mortality and incidence of coronary events. The Cox regression method (17) was used to compare the treatment group iife table curves for mortality and incidence of coronary i : vents both unadjusted and adjusted for baseline differenc es. The variables used for the Cox adjusted analyses were:hosen by a method using the variables that produced the greatest amount of adjustment to the treatment difference (18) . In general, these variables are those most highly associated with the end point and those differentially distributed between the two treatment groups. A test for homogeneity of log odds ratios (19) was used to evaluate the interaction of mexiletine treatment with each of 141 baseline variahles.
All patients were included in the analysis of the results and were always counted ill the treatment group to which they were originally randomized.
The primary end point, as just defined, was frequent or complex cardiac arrhythmia based on the 24 hour ambulatory electrocardiograms taken at months 4 and 12 after entry; month 4 to assess short-term effects and month 12 to assess long-term effects. Month 4 was selected rather than month I because it was expected that the patients would be more stable 4 months after the acute event than at I month. The test for comparison of two proportions was carried out to evaluate the efficacy of mexiletine compared with placebo treatment with respect to the primary end point. For the primary end point, as well as for total mortality, a Z value in excess of ± 1.96 (p < 0.05) was considered to be statistically significant. The mexiletine and placebo treatments were also compared with respect to the primary end point at month I and for a number of additional measures of cardiac arrhythmia (for example, total premature ventricular complex count, total number of runs and other 24 hour electrocardiographic measurements at months I, 4 and 12) as well as for multiple measures of drug safety and toxicity. The numerous statistical tests increase the likelihood that a statistically significant difference will be observed when there is no true difference between the two treatment groups. The need for adjustment of the critical Z value is generally accepted, but no single or simple solution is available. Therefore, the investigators decided in the planning phase that for response variables other than the primary end points just mentioned, Z values in excess of ± 3.0 would be considered statistically significant, and those in the range ± 2.6 to 3.0 would be considered of borderline significance.
Since loss of information because of death could obscure the true effects of mexiletine on cardiac arrhythmia, one analysis attempts to take account of all deaths. In this analysis, patients who died and did not have electrocardiographic changes before death were also counted as having frequent or complex cardiac arrhythmia.
Results
Baseline comparability of treatment groups. The distribution of selected baseline characteristics is given in Table  1 . The distributions of 169 baseline variables (listed in Appendix) were examined; the treatment differences for 12 of these (7. 1%) yielded absolute Z values of 1.96 or greater, a proportion only slightly higher than expected to occur by chance. The baseline distribution of frequent or complex cardiac arrhythmia showed some imbalance, with more patients in the placebo group than in the mexiletine group having this finding (Z value = -1.78); the imbalance was due to the distribution of runs of three or more premature ventricular complexes. Therefore, in one of the analyses of this end point, the occurrence of the primary arrhythmia end point during follow-up was considered for patients with and without such findings at baseline. A Z value of -1.96 was obtained for the mexiletine-placebo comparison of another electrocardiogram variable, cardiac arrhythmia (defined in Table 1 ).
The mean number of days from onset of symptoms of IMPACT RESEARCH GROUP the qualifying myocardial infarction to initiation of treatment was 11.2 days in the mexiletine group and ILl days in the placebo group (range 4 to 24). Overall, the groups were relatively comparable at baseline study, although an imbalance with respect to one arrhythmia variable was noted.
There is no evidence that the protocol for issuing treatment allocations was not followed in the assignment of treatment to any of the 630 enrolled patients. Effects ofmexiletine on arrhythmia. Altogether 2,292 ambulatory 24 hour electrocardiograms were obtained (89.6% of those scheduled). Of these, 66.8% had 23 or more hours of ana lyzable data, 90.7% had more than 20 hours and 4.6% (106 tapes) were unanalyzable.
The occurrence offrequent or complex cardiac arrhythmia in the mexiletine and placebo groups at baseline and follo w-up visits with ambulatory 24 hour electrocardiograms is given in Table 2A . A significant reduction in the occurrence of the primary end point was observed in the mexiletine group compared with the placebo group at months 1 and 4 after entry, yielding Z values of -5.04 and -3.98, respectively. The corresponding differences at month 12 was in the same direction, but was not significant. There was a large increase in the number of patients with this end point at month 1 (58.0%) compared with baseline (37.6%) in the placebo group. The corresponding change in the mexiletine group was much smaller, that is, 36.5% at month I compared with 30.7% at baseline. In the placebo group, the percent of patients with frequent or complex cardiac arrhythmia was somewhat lower at month 12 than at months 1 and 4, whereas in the mexiletine group the percent with this finding was higher at month 12 than at months I or 4. The occurrence of the primary end point in the cohort of patients with 24 hour electrocardiograms at baseline and at months 1, 4 and 12 was also examined; the findings were very similar to those for all patients. The mexiletine-placebo differences in the occurrence of frequent or complex cardiac arrhythmia for patients with and without that finding at entry were also similar to the differences observed for all patients.
An analysis taking account of deaths in each group is presented in Table 2B . The findings are essentially the same as in the previous analyses.
About twice as many patients in the placebo group as in the mexiletine group had runs of three or more premature ventricular complexes at months 1 and4; these drug-placebo differences were statistically significant based on study criteria (Table 2C) . At month 12, there was a slightly, but not significantly, higher percentage of patients with runs of three or more premature ventricular complexes in the mexiletine group than in the placebo group. The results for other electrocardiographic end points are presented in another study report (20) .
Mortality. After an average follow-up of 9 months, there were 24 deaths (7.6%, standard error = 1.5%) in the mexiletine group compared with 15 deaths (4.8%, standard error = 1.2%) in the placebo group (Z value = 1.45) ( Table 3) .
Of the 39 reported deaths, 35 were attributed to cardiovascular disease, 21 in the mexiletine group and 14 in the placebo group. Seven deaths (2.2%) in the mexiletine group and four deaths (1.3%) in the placebo group were sudden, that is, occurring within I hour of onset of symptoms.
Life table rates for total mortality were higher in the mexiletine than in the placebo group (Fig. I) . The Cox Z value for the comparison of these curves was 1.47 (unadjusted) and 1.47 after adjusting for 10 baseline characteristics (identified in Appendix).
Mortality was examined among the 17 patients in the mexiletine group and 3 patients in the placebo group who had been reported to have cardiac arrest between the onset of the qualifying myocardial infarction and entry into study. Only one (a mexiletine-treated patient) of these patients died during the follow-up period.
Among 15 .2% (14 of 92) died in the mexiletine group and 5.4% (6 of 112) died in the placebo group. The test for homogeneity yielded a Z value of 1.67. There were 32 patients (17 mexiletine-treated and IS placebo-treated) who could not be classified and were not included in the analysis.
Interaction of treatment with each of 141 baseline variables was assessed for total mortality rate. The variables for which there was a suggestion of interaction with treatment were systolic blood pressure and Myocardial Infarction Research Unit (MIRV) classification (21) . Among patients with a baseline systolic blood pressure of less than l lf mm Hg, there were 14 deaths (8. 1%) in the mexiletine group compared with 2 deaths (1.2%) in the placebo group. Corresponding results for patients with a systolic blood pressure of l l S mm Hg or greater were 10 deaths (6.9%) and 13 deaths (8.8%) in the mexiletine and placebo groups, respectively. The test for homogeneity yielded a Z value of 2.44, which was not statistically significant. In patients in MIRV class I (no heart failure and no signs of cardiac decompensation), there were 10 deaths (4.0%) in the mexiletine group and 12 deaths (4.8%) in the placebo group. In patients in class II (heart failure) and III (severe heart failure), there were 14 deaths (20.6%) in the mexiletine group and 3 deaths (4.8%) in the placebo group. The Z value of 2.31 for the test for homogeneity was not statistically significant. Among mexiletine-treated patients with some evidence of heart failure, half had a systolic blood pressure of less than l l S mm Hg with eight deaths (23.5%) and half had a systolic blood pressure of l l S mm Hg or greater with six deaths (17.6%). Approximately half of the 63 placebo-treated patients with some evidence of heart failure had a systolic blood pressure of l l S mm Hg or greater with three deaths (9.7%). There were no deaths in the placebo group with some evidence of heart failure and a low systolic blood pressure at baseline.
Other events including side effects. Findings for other fatal and nonfatal events are given in Table 4 . Fewer patients in the mexiletine group than in the placebo group were hospitalized for angina pectoris (Z value = -1.58) or cardiovascular surgery (Z value = -1.68). More mexiletinethan placebo-treated patients had pulmonary embolism (Z value == 1.99). None of these differences was statistically significant. Life table rates for incidence of coronary events (coronary death or nonfatal myocardial infarction) showed no treatment differences (Fig. 2) .
In regard to use of nonstudy medication during the trial, more rnexiletine-than placebo-treated patients reported using tricyclic antidepressants or hypnotics, sedatives and barbiturates (Table 5) . Patient complaints occurred almost as frequently in the placebo group as in the mexiletine group (Table 6 ). Significantly more mexiletine-than placebo-treated patients complained of tremor and loss of consciousness, nausea and constipation; these differences were of borderline significance.
Follow-up and adherence. Of the 630 patients enrolled, 566 completed the final visit and 39 were reported to have died. The remaining 25 patients were known to be alive as of August 31, 1982. Overall, 93.8% of all scheduled visits were completed, 92.9% in the mexiletine group and 94.6% in the placebo group.
Adherence to assigned study medication was assessed at each follow-up visit by pill count, questioning the patient and analysis of serum mexiletine levels. It was estimated that 12.7% of patients in the mexiletine group and 9.9% of patients in the placebo group took less than 10% of study medication at 50% or more of all visits. For the mexiletine group 76.3% and for the placebo group 83.1% of the patients were on full dosage at the last completed follow-up visit before the final visit.
The major reasons why study medication was reduced or discontinued in the mexiletine group were tremors , insomnia, epigastric pain and nausea ( Table 7) . The main reason for reduced dosage or stopping medication in the placebo group was antiarrhythmic treatment not including beta-receptor blocking agents.
Blood specimens were taken at each follow-up visit and forwarded to the Central Laboratory for measurement of serum mexiletine levels. Twenty-five percent of patients in the mexiletine group had serum mexiletine levels of 0.7 jLg/ml or greater (presumed therapeutic level) for at least 75% of all visits and 16.4% had serum mexiletine values of 0.2 jLg/ml or less for at least 75% or more of all follow-up visits (Table 8) . A few patients (6.7%) in the placebo group had serum mexiletine values greater than 0. 2 jLg/ml. An external quality control program included submission of two aliquots of the same specimen at different time periods for analysis at the Central Laboratory. For one pair of the 36 placebo pairs submitted , the test for mexiletine was positive in one of the two aliquots of the same specimen , but not the other .
Occurrence of events in subgroups classified by assessment of adherence. For the mexiletine-treated patients with a serum mexiletine level of 0 .7 jLg/ml or greater, the occurrence of frequent or complex cardiac arrhythmia at month I was 28 .2% compared with 48.3% for patients with a serum mexiletine level of 0 .2 ILg/ml or less (Table 9 ).
These findings must be interpreted with caut ion since there is no assurance that patients with a high level of serum mexiletine were comparable with those patients with a low Occurrence offrequent or complex cardiac arrhythmia at any follow-up visit (at months 1,4 or 12) was determined for patients with good and with poor adherence (Table 10) . The former was defined as 90% adherence to full prescription at months 1, 4 and 12. The percent of mexiletine-treated patients with the primary arrhythmia end point at any visit was less for good adherers than for poor adherers (45,2 versus 57.8%, respectively). Little difference was noted for good and poor adherers among placebo-treated patients (65. 13.9% respectively). The same cautionary note as mentioned for the analysis of the biochemical adherence assessment applies to this analysis .
Discussion
Effect on cardiac arrhythmia. Overall , the results for the primary cardiac arrhythmia end point indicate that mexiletine was quite effecti ve in reducing the risk of arrhythmia during the first 4 months after discharge from the hospital. The differences were primaril y due to the large increase compared with baseline in the percent of placebo-treated patient" with this end point at I and 4 months after entry ; approximately 60% at months I and 4 compared with 38% before initiation of treatment. The increase in the occurrence of arrhythmia after discharge from hospital has been observed by others (9 ,22) . Although there were 20 more patients In the placebo-treated group than in the rnexiletine group who had frequent or complex cardiac arrhythmia before the initiation of treatment, this difference did not account for the large and statistically significant differences observed during the follow-up visits.
Effect on mortality. The marked difference in occurrence of frequent or complex cardiac arrhythmia in mexiletine-treated patients compared with the placebo-treated patients was not accompanied by a reduced mortalit y rate . The percent of patients who died was 7.6 and 4.8% in the mexiletine and placebo groups, respectively; this difference was not statistically significant.
The mortality results for a large number of subgroups defined by baseline characteristics were examined to determine whether any group showed favorable trends or appeared adversely affected by mexiletine treatment. These analyses showed a larger mexiletin e-placebo difference if patients had some evidence of heart failure (MIRU class II or III) or a systolic blood pressure of less than liS mm Hg, or both , than if these clinical findings were not present , but the log odds ratio tests for interaction were not significant. Thus, these findings are suggestive , but not conclusive .
Side effects. More patient s in the mexiletine than in the placebo group reported central nervou s system and gastrointestinal problems and used more medication for central nervous system problems. These adverse reactions have been observed in previou s studie s of mexilet ine (4-7,9), but the occurrence of side effect s severe enough to result in reducing dosage or stopping the sustained release form of the drug was less than that reported in studies that used the regular form of the drug (4) (5) (6) (7) 9) . No previou sly unreported side effects were observed in this study.
Serum drug levels. Serum mexiletine levels were generally lower than those observed in studies with the regular form of the drug reportin g comparable data (5-7,9) and substantially lower than those observed in a short-term study of the sustained release form (8) . There is no obvious ex- *Patients who did not have at least one follow-up visit adherence value and at least one follow-up visit 24 hour electrocard iogram. Good = 90% adherence and prescription = two capsules at all visits (I , 4 or 12 months) with adherence items answered. Poor = less than 90% or less than two capsules at anyone of the follow-up visits at month I. 4 or 12.
planation for the low serum levels observed in IMPACT. Despite low serum levels, mexiletine-treated patients had significantly less cardiac arrhythmia at months 1 and 4 than did placebo-treated patients. It would have been desirable to have had blood specimens taken for measuring serum mexiletine levels and 24 hour electrocardiographic recordings at the end of the first 3 days of treatment and before hospital discharge. These procedures would have provided useful information to define the levels of serum mexiletine associated with antiarrhythmic effects.
Results of other studies compared with IMPACT. Findings observed in IMPACt on the occurrence of frequent or complex cardiac arrhythmia at months 1 and 4 were similar to those in the placebo-controlled trial of mexiletine conducted in the United Kingdom (9) in patients at high risk of sudden death. In that study, the hourly number of premature ventricular complexes was significantly reduced by mexiletine at 1 and 3 months after initiation of treatment. Doublets and multiform beats were also significantly less frequent in the mexiletine than in the placebo group 1 month after entry. In this study, after 3 months of treatment and 4 months of follow-up study, there were 13.2 and 11.6% in mexiletine and placebo groups, respectively. An unfavorable trend in mortality was also observed in IMPACT mexiletine-treated patients who were in MIRU class II and III. Observed life table cumulative mortality rate for all patients at the end of 4 months in IMPACT was 5.5% in the mexiletine group and 3.0% in the placebo group. At the end of 12 months, the life table cumulative mortality rate in the mexiletine and placebo groups in IMPACT was 9.1 and 6.3%, respectively.
A review by May et al. (23) of clinical trials assessing short-term intervention after myocardial infarction was published in 1983. These investigators summarized the studies of antiarrhythmic drugs as follows: four antiarrhythmic drugs (disopyraniide, lidocaine, procainamide and quinidine) were evaluated in 14 trials that satisfied minimal review criteria (a total study size of at least 100 patients, with random assignmerit of participants to treatment). Each agent was reported to suppress ventricular arrhythmia during the acute phase of a myocardial infarction. Not one of the trials demonstrated that suppression of arrhythmia was accompanied by a statistically significant reduction in the overall mortality rate. Most of the trials randomized fewer than 250 patients and, therefore, these studies had little power to detect differences in mortality unless the true difference was 40% or greater. A review (24) of long-term controlled trials published in 1983 considered six clinical trials of antiarrhythmic agents (aprindine, mexiletine, phenytoin and tocainide) in patients with myocardial infarction. In four trials in which cardiac rhythm was monitored, the drugs tested were reported to be effective in reducing occurrence of ventricular arrhythmias and ectopic beats. Despite that finding, there was no statistically significant evidence that antiarrhythmic therapy prolonged life in these patients with myocardial infarction. Two trials showed a favorable trend in mortality. All but one study randomized fewer than 250 patients to each treatment group and, thus, these studies would only detect large differences in the overall mortality rate.
Three controlled trials (25) (26) (27) have shown a significant reduction in the total mortality rate and sudden death in patients treated after myocardial infarction with beta-receptor blocking drugs compared with patients treated with placebo. One recent trial (28) had a favorable trend and another (29) showed no difference. It is unclear whether the reductions in mortality rate were due to the antiarrhythmic effects of the beta-receptor blocking agent or some other action.
Conclusions. IMPACT as well as other studies have demonstrated the antiarrhythmic efficacy of mexiletine, but the mortality findings suggest that the suppression of ventricular premature complexes and arrhythmias in patients after myocardial infarction may not result in a reduced mortality rate. This is in contrast to treatment with beta-receptor blocking agents, where an antiarrhythmic effect may be one of the goals. IMPACT did not address the question of whether patients treated after myocardial infarction with beta-receptor blocking drugs compared with patients treated with placebo. One recent trial (28) had a favorable trend and another (29) showed no difference. It is unclear whether the reductions in mortality rate were due to the antiarrhythmic effects of the beta-receptor blocking agent or some other action. 
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